Ablynx NV has raised €50 million in a secondary offering of its shares to support the development of its portfolio of therapeutic proteins based on single-domain antibody fragments. The company now has a market capitalisation of about €327 million.
Ablynx NV has raised €50 million in a secondary offering of its shares to support the development of its portfolio of therapeutic proteins based on single-domain antibody fragments. The company now has a market capitalisation of about €327 million.